Arterial and Venous Thrombosis in COVID-19 disease: From Molecular Pathway to Vaccine Administration

Francesco Nappi, MD1; Adelaide Iervolino, MD2; Sanjeet Singh Avtaar Singh, PhD3

1 Department of Cardiac Surgery, Centre Cardiologique du Nord. 93200 Saint-Denis, France
2 Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCSS.
3 Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom

Corresponding author
Francesco Nappi, MD
Cardiac Surgery, Centre Cardiologique du Nord de Saint-Denis
36 Rue des Moulins Gémeaux, 93200 Saint-Denis, France
Tel: +33149334104
Fax: +33149334119
Email: francesconappi2@gmail.com

Abstract
The Coronavirus 2 (SARS-CoV-2) infection is a global pandemic that has affected millions of people worldwide. The advent of vaccines, however, has permitted some restitution. Aside from the respiratory complications of the infection, there is also a thrombotic risk attributed to both the disease alongside the vaccine. There are no reliable data for the risk of thromboembolism in SARS-CoV-2 infection in patients managed out with the hospital setting. A literature review was performed to identify the pathophysiological mechanism of thrombosis from the SARS-CoV-2 infection including the role of Angiotensin-Converting Enzyme receptors. The impact of the vaccine and likely mechanisms from thrombosis following vaccination was also clarified. Finally, the utility of the vaccines available against the multiple variants is also highlighted.

The systemic response to SARS-CoV-2 infection is still relatively poorly understood, but several risk factors have been identified. The roll-out of the vaccines worldwide has also allowed the lifting of lockdown measures and a reduction in the spread of the disease. The experience of the SARS-CoV-2 infection, however, has highlighted the crucial role of epidemiological research and the need for ongoing studies within this field.

Keywords: Arterial and Venous Thrombosis; COVID-19 disease; SARS-CoV-2 infection; vaccines
**Introduction**

Patients with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection may develop associated arterial and venous thrombotic complications. Data reported in the 2019 U.S. Coronavirus Disease Patient Registry (COVID-19), recorded a 2.6% rate of thrombotic complications in the 299 patients who required non-critical hospitalization compared to the rate of 35.3 % of the 170 patients for whom hospitalization was placed in critical condition [1,2]. Klok et al confirmed a remarkably high 31% incidence of thrombotic complications in ICU patients with COVID-19 infections[2]. These results supported the recommendation to strictly use drug prophylaxis for thrombosis in all COVID-19 patients admitted to the ICU. The data strongly supported increased drug prophylaxis dosage, even in the absence of randomized trials.

To date, there are no reliable data to establish the risk of thromboembolism in SARS-CoV-2 infection in patients whose clinical conditions exclude hospitalization. Several studies reported that patients admitted to the hospital with Covid 19 disease experienced thrombotic complications involving the heart, brain, and peripheral vascular system and which mainly led to myocardial infarction (MI), ischemic stroke, and venous thromboembolism (VTE) [3-5]. During the initial months of the pandemic acceleration, several autopsy studies [6,7] have highlighted the presence of systemic microthrombi displaced in many organs, including lungs, heart, and kidneys, which have suggested how thrombosis could contribute to the determination of frequent and often fatal multisystem organ failure in patients with severe COVID-19 disease [8,9].

1. Angiotensin-Converting Enzyme (ACE) 2 Receptor: The Evolutionary Stage of Infection from Himalayan Palm Civet and Bat Coronavirus to SARS Cov2 infection

The gateway for SARS-CoV-2 to target cells is the angiotensin-converting enzyme (ACE) 2 receptor, which is mostly expressed by epithelial cells of the lung, heart, blood vessel, kidneys, and intestines. The ACE family of receptors includes both ACE and ACE2 which, although they are dipeptidyl mono-carboxydipeptidases with distinct physiological functions.

1.1 Structure of the ACE as ligand-binding receptors

SARS-CoV2 uses common cellular transmission which is based on the binding of ligands to specific cell surface receptors. ACE2 is a G protein-coupled receptor (GPCR) and belongs to a category of receptors that play a central role in the initiation and regulation of cellular processes [10]. They constitute the most prominent class of receptors implicating pathological disorders of the cardiovascular, respiratory, endocrine, immune, and neural systems. Activation of GPRs is also common in neoplastic pathologies. The function that GPCRs exert is manifold by mediating responses to specific interactions with hormones, neurotransmitters, pathogens, metabolites, ions, fatty acids, and drugs [11,12].

ACE / GPCR is an integral membrane protein-expressing an extracellular N-terminal and seven helical TransMembrane (TM) domains, TM1 to TM7 interconnected by link regions. The signaling function of GPCR is carried out using a precise sequence of mechanisms based on the binding to very different types of extracellular stimulation that lead the domain of the TM to change the conformation with a process of structural remodeling of the protein [13]. These conformation changes induce coupling with cytoplasmic proteins and subsequently the activation of enzymes that lead to the generation of a second messenger. Once the second messenger is formed it can activate a sequence of signals inside the cell [14]. This specific role of GPCRs with increasing levels of intracellular cyclic Adenosine Monophosphate – (cAMP) represents the pivotal pathway in response to ligands, such as signaling of the renin-angiotensin system (RAS). It is important to underline that the levels of cAMP production in the cellular domain are modulated by several factors. Multidrug Resistance Proteins (MRPs)
allow the efflux of cAMP from the inside of the cell to the extracellular fluid, thus maintaining homeostatic intracellular concentrations. The role of transporters exercised by MRPs serves to regulate the balance of cAMP within the cell.

Lu et al [15] reported concern about the structural conformation of the ACE / GPCR complex and its interaction with SARS CoV by focusing on lipid rafts. The structure, activation, and signaling of the ACE / GPCR complex are strongly influenced by the bilayer domain with specific membrane-GPCR interactions [16]. It has been shown that some subsets of GPCR are preferentially isolated in distinct regions of the membrane defined as lipid rafts [17-19]. Evidence has shown that lipid rafts serve as an entry site for SARS CoV. For example, lipid rafts in Vero E6 cells were involved in the coronavirus entry of severe acute respiratory syndrome (SARS-CoV). As has been clarified by the tests after SARS CoV infection, the integrity of the lipid rafts was a necessary requirement to produce the pseudotyped SARS-CoV infection. If plasma membrane cholesterol depletion was induced using the relocalized MbetaCD marker on the caveolin raft the SARS-CoV ACE2 receptor was not significantly modified. Although the surface expression of ACE2 still allowed binding to the virus, treatment with MbetaCD inhibited the infectivity of the pseudotyped SARS-CoV by 90%.

The observed data concerns the ectodomain of the SARS-CoV protein S (S1188HA) which can be associated with lipid rafts. The spike protein, after binding to its receptor, colocalized with the ganglioside marker GM1 residing on the raft. The study found that S1188HA binding was not affected by plasma membrane cholesterol depletion supporting the conclusion that lipid rafts serve as a gateway for SARS-CoV [20].

Given the knowledge we have, there is still no clarity on the extent to which SARS-CoV-2 increases the risk of thromboembolism. A study performed in the United Kingdom compared 1877 patients discharged from hospital after COVID-19 disease and 18 159 hospitalized for a non-COVID-19 disease reporting no difference in hospital-associated VTE rates (4.8 / 1000 vs 3.1 / 1000 ; odds ratio, 1.6 [95% CI, 0.77-3.1] ; P = .20) [21]. One point to clarify is whether the high rate of VTE is specific to patients who develop COVID-19 or if VTE is mainly occurring in patients with a major overall criticality of the disease and for the complications that arise.

1.2 Function of ACE receptor

The function of ACE is to split angiotensin I into angiotensin II, which binds and activates the type 1 angiotensin II receptor. This activation triggers a series of pathophysiological mechanisms that ultimately have vasoconstrictors, proinflammatory, and pro-oxidative effects. It is important to underline that among the functions of ACE2 there is the hydrolytic degradation of angiotensin II to angiotensin 1-7 and angiotensin I to angiotensin 1-9. Once angiotensin 1-9 is generated it binds to the Mas receptor, producing anti-inflammatory, antioxidant, and vasodilatory reactions. From a pathophysiological point of view, it is important to distinguish two forms of ACE2 receptor. A type 1 integral transmembrane protein with the structural characteristics of representing the extracellular domain that acts as a receptor for the SARS-CoV-2 spike protein. A soluble form representing circulating ACE2 [22,23]. To date, our knowledge is limited on the relationship that is established between SARS-Cov 2 and the two forms of the receptor. A better understanding of this relationship may more precisely define the operational adaptive or maladaptive processes that sustained COVID-19 infection.

1.3 ACE receptor and binding to human coronary viruses

The knowledge we have on the interaction between the ACE2 receptor of Humans (hACE2) and the Himalayan palm civet receptor (cACE2) with SARS-CoV derives from the usage of the receptor by the Human (hSARS-CoV) and Himalayan palm civet coronavirus (cSARS-
The hSARS-CoV can bind both hACE2 and cACE2 receptors while the palm civet coronavirus has no interaction with the ACE2 receptor expressed in humans. It is known that the adaptation of cSARS-CoV to humans was determined by two point mutations, recognized as K479N and S487T, in the binding domain of the SARS-CoV spike protein (SARS-Cov-S) [24].

The mutations that have recently characterized SARS-Cov2, led to more aggressive variants of the virus and the concept of adaptive mutations as noted by Wu et al [25] with strengthened receptor binding and tropism (RBT). The authors demonstrated that adaptive mutations of RBT led to the identification of genetic mutations of the virus that enhanced interaction with human or palm civet ACE2. The genetic adaptation processes that took place between hSARS-CoV and cSARS-CoV could also be recorded in SARS-CoV-like viruses that have been isolated in bats [26]. A previous study found that the pathways in which bat coronaviruses infected host cells did not occur through the interaction of the ACE2 receptor with expressed SARS-CovS and remained a mystery. However, the important finding remains that the substitution of the amino acid sequence found between residues 323 and 505 of the corresponding sequence of the SARS-CoV-S / RBT is sufficient to allow the use of the human ACE2 receptor [26].

The first demonstration of the possibility that a SARS Cov2 interacts with the human ACE2 receptor is reported in the landmark study from the University of North Carolina at Chapel Hill [27,28]. The authors reported the substantially high risk of SARS-like bat coronavirus disease named SHC014-CoV circulating in Chinese horseshoe bat populations. This type of coronavirus has a high binding affinity with the ACE2 receptor [29]. SARS CoV2 was obtained using the reverse genetics technique through the generation and characterization of a chimeric virus. The new SARS-CoV2 virus expressed the bat coronavirus SHC014 spike in a mouse-adapted SARS-CoV backbone. The evidence showed at least two very interesting findings. The first was that group 2b viruses encoding the SHC014 peak in a wild-type backbone could efficiently use more orthologs of the human angiotensin II converting enzyme (ACE2) than the SARS receptor. The second was that group 2b viruses could replicate efficiently in primary human airway cells and that it was also possible to obtain in vitro viral titers equivalent to the epidemic strains of SARS-CoV. Once these results were translated in vivo, replication of the chimeric virus in the mouse lung demonstrated considerable pathogenesis. This led to the futile immunotherapeutic and prophylactic modalities to cope with SARS-CoV infection which had poor outcomes. In fact, both monoclonal antibodies and the vaccine approach failed to neutralize and protect against CoV infection using the new SARS CoV-S. Based on these results, the authors synthetically re-derived an infectious full-length recombinant SHC014 virus and demonstrated robust viral replication both in vitro and in vivo. This landmark report suggested 6 years ago that there was a potential risk of SARS-CoV re-emergence from viruses circulating in bat populations.

Coronaviruses can enter target cells effortlessly due to their to equally exploit many cell surface molecules such as proteins and carbohydrates. Lecithins play a fundamental role in this process. For example, host calcium-dependent (type C) lectins have been recognized to play a central role in SARS-CoV2 infection. Evidence suggests a specific intercellular role exerted by non-integrin 3-grabbing adhesion molecule (DC-SIGN) of dendritic cells. This is a type C lectin expressed on macrophages and dendritic cells that function to recognize the high-mannose glycosylation patterns commonly found on viral and bacterial pathogens. Coronavirus protein S is highly glycosylated providing the virus with the opportunity to interact with host lectins such as DC / L-SIGN. L-SIGN, which is expressed on liver and lung endothelial cells, has been reported as an alternative receptor for SARS-CoV and bat coronavirus type HCoV-229E [30,31].
1.3 The role of ACE2 in COVID-19 pathogenesis

A role of the ACE2 receptor has been hypothesized in the pathogenesis of Covid-19, especially with regards to its potential effects on the most vulnerable patients presenting with cardiovascular co-morbidities.

Covid 19 does not have the same impact on the population with an exponential increase in the severity of the disease as well as mortality, due to devastating thromboembolic complications, occur in patients over the sixth decade of life with comorbidities such as cardiovascular disease and diabetes.

The angiotensin-converting enzyme 2 receptors (ACE2) serve as the attachment site of the SARS-CoV-2 spike protein to enter lung epithelial cells [32]. Upregulation with increased ACE2 expression has been demonstrated in patients with cardiovascular disease and diabetes treated with angiotensin-converting enzyme (ACEI) inhibitors and angiotensin receptor blockers (ARBs). However, whether this condition can lead to greater COVID-19 severity has not been fully clarified.

Discussions related to the use of ACEI/ARB have surfaced regarding the need to continue therapy in patients taking the aforementioned drugs. The current recommendations are to discontinue the administration of these drugs, despite diverging opinions, which were not received by experts due to the lack of strong evidence [33]. ACE2 not only plays a role in the pathogenesis of COVID-19 but also as a component of renin-angiotensin system signaling (RAS) and localized throughout the body. Although the evidence has conclusively revealed that ACE2 works to allow SARS-CoV-2 to enter cells, it nevertheless plays a central anti-inflammatory role in RAS signaling by converting angiotensin II, the representative for the inflammatory process, into angiotensin 1-7, which leads to anti-inflammatory futures [34]. A study performed on the lungs of rats [35] showed that the reduced expression of ACE2, leads to a sequence of major proinflammatory processes that are exacerbated by age and therefore attributable to a dysregulation of RAS signaling throughout the body [36].

It is important to note that this typical inflammatory profile, even in accentuated forms, supports pathophysiological processes that represent the main feature of hypertension and diabetes, as well as being very widespread in old age [36]. The upregulation of the ACE2 receptor in subjects with diabetes and hypertension treated with AC1 / ARBs must be seen as a restorative substrate that has a physiological function. The process that unfolds during SARS Cov2 infection sees ACE2 as a gateway for the virus to enter cells, but the reduction of its expression in older people and those with CVD can potentially predispose to more severe forms of the disease. The ACE2 receptor has the dual function of facilitating SARS Cov2 infection but at the same time the fundamental anti-inflammatory function, linked to RAS signaling, is reduced because it is compromised in patients who develop Covid 19. In fact, data provided by the first SARS epidemic in 2003 demonstrated the double role of the ACE receptor, thus delineating the predisposing factors to the occurrence of the disease and its severity [34].

Given the reports from the two previous pandemics supported by Sars Cov and Mers CoV, the coronavirus disease 2019 denotes a difference in the predisposing factors to the occurrence of the disease and its severity. In the previous epidemic, high mortality occurred in the youngest subjects aged between 40 and 50 who also represented the largest number of infected in the population. In the younger population, the course of the disease was worse with a higher risk of critically illness hospitalization and mortality than in older people with pre-existing comorbidities [37].

Likewise, in SARS CoV2 infection it is plausible that the higher expression of ACE2 leads to a greater predisposition to experience the disease. Epidemiological data from the South Korean population, where genetic testing has been widely used in individuals, reported higher
numbers of infected among young adults [38] or those with increased ACE2 levels are likely. In this regard, an Italian study, examining the severity of COVID-19 disease in the elderly population with CVD, hypothesized that a reduction in AC2 levels due to aging and CVD coupled to the upregulation of the proinflammatory angiotensin II pathway are factors that likely predispose older individuals to severe forms of COVID-19. Since SARS CoV2 in carrying out its infectious action itself uses the ACE2 receptor, thus leading to a reduced expression of ACE2 on the cell surface, an upregulation of angiotensin II signaling in the lungs results in the development of acute damage [34]. The consequence of these morphofunctional and biochemical changes can predispose elderly individuals with CVD, who have reduced levels of ACE2 compared to young people, to the emergence of exaggerated inflammation further reduction of ACE2 expression in the context of COVID-19. In these cases, the disease manifests itself with greater severity. Observations received suggest that older individuals, especially those with hypertension and diabetes, have reduced ACE2 expression and upregulation of proinflammatory angiotensin II signaling. Therefore the morphofunctional and biochemical changes can be corrected by the increase in ACE2 levels induced by ACEI / ARB treatment. First, it is possible to hypothesize that in COVID-19 disease, the binding of SARS-CoV-2 to ACE2 acutely exacerbates this proinflammatory background, predisposing these subpopulations to greater severity and mortality of COVID-19 disease (Figure X). Second, considering this hypothesis credible, a protective role of the antagonistic action of angiotensin II against acute lung injury associated with sepsis could be effective. This supports the use of continuous therapy with ACEI / ARB [39-40].

Third, the aforementioned biomechanical modifications of the receptor, plausible with aging, should be investigated. Therefore, experiments on the functioning, the regulatory mechanisms of RSA, and the biomechanics of the receptors involved in these functions should be implemented. Specifically, the biophysical mechanisms underlying the associated remodeling of the lipid membrane remain to be clarified. They [41] may be useful in the prevention of fatal lung complications caused by genetic variants of the Wuhan virus.

1.4 ACE inhibitors and Angiotensin type II blockers role in Covid-19 severity

Tetlow et al [42] did not identify any associations between ACE-I/ARB use and AKI, macrovascular thrombi or mortality. Other studies [43,44] also supported the non-discontinuation of these drugs during hospitalization from Covid-19.

Among them, in fact, a large fraction is being administered either ACE inhibitors or Angiotensin II blockers, due to epidemiological data showing cardiopathies, diabetes mellitus and hypertension to be the most frequent comorbidities found among those patients [45]. The up-regulation of ACE2 expression, possibly altered by drug administration, has not been defined but associated with severity of the disease.

Several preceding studies have demonstrated that the risk of developing COVID-19 after the administration of ACEi and ARBs raised significantly. This could be an indirect effect of overproduction of the circulating ACE2 transcripts in the cells [46, 47]. As an instance, Enalapril, which is a frequently used ACEi, was reported to increase ACE2 expression in the kidney tissues [48].

Concerning possible therapeutical targets, instead ACE2 blockers have been developed, such as the small synthetic inhibitor N-(2-aminoethyl)-1aziridine-ethanamine (NAAE) [49]. It is able to bind ACE2 in its closed conformation so that molecular interaction between the viral particle and the receptor cannot be possible and fusion does not happen. Thus, NAAE could exert dual inhibitory effects: one on ACE2 catalytic activity and another on SARS binding [50]. Despite this, current research drives opinions towards a cautelative use of this agent.
2. Pathophysiology of Arterial and Venous Thrombosis

To date, the complete pathophysiology profile of arterial and venous thrombosis during Covid 19 disease has not yet been fully clarified. The literature reports prothrombotic abnormalities in patients with COVID-19. In a Chinese study [51] performed in the first phase of the SARS Cov2 epidemic, 19 patients with COVID-19, who presented with critical clinical conditions, recorded elevated levels of markers of hypercoagulability such as D-dimer found in 100%, fibrinogen in 74%, and factor VIII in 100%. The dysregulation of the coagulation process included the presence of antiphospholipid antibodies in 53% of the population studied. However, reduced levels of protein C, protein S, and antithrombin were noted in all patients. Complications such as stroke arterial ischaemia and VTE intervened with the coagulation disorder.

Zaid et al studied 115 patients with COVID-19 disease reporting that SARS Cov2 directly interferes with platelets. Viral RNA and high platelet-associated cytokine levels were found in the platelets of all study participants. These abnormalities were not related to the severity of the disease because in 71 infected individuals the disease was in a non-serious manner while for 44 patients hospitalization was required for critical clinical conditions. Specific tests performed on platelets showed aggregation at lower than expected thrombin concentrations [52].

Nicolai et al examined the autopsy findings of 38 individuals who died with COVID-19 which showed that histopathological changes in coagulation were marked in the vessel microcirculation. The abnormalities recorded were microvascular thrombotic formations, neutrophil extracellular traps, which were characterized by networks of extracellular neutrophil-derived DNA and aggregated neutrophil platelets [53]. The authors compared the peripheral blood of patients with Covid 19 with that of healthy patients. In vitro responses on peripheral blood samples from the 3 infected patients exhibited excessive platelet and neutrophil activation, as assessed by degranulation and integrin IIb-IIIa activation and immunofluorescence, compared to healthy control patients samples.

2.1 The inflammatory response during Sars Cov2 infection and thrombotic complication

Histopathology of SARS infection Cov2 is distinguished from that caused by other viruses with tropism for the respiratory tract. Sars Cov2 leads to direct damage of endothelial cells characterized by a dense perivascular infiltration of T lymphocytes combined with aberrant activation of macrophages. The excessive and uncontrolled inflammatory response, endothelial cell apoptosis, thrombotic microangiopathy and angiogenesis are other distinctive histopathological features that denote the aggressiveness of SARS Cov2, which may be responsible for clinically severe forms of Covid 19 thus conferring the characteristics of a distinctive disease not comparable to any other viral respiratory disease [54].

The significant finding that emerges in the evaluation of the pathophysiology of thromboembolism in COVID-19 versus non-COVID-19 disorders may be that the coagulation alterations may be more mediated either by platelet-dependent activation and intrinsically related to viral-mediated endothelial inflammation. Another distinguishing feature of thrombosis during SARS Cov2 infection is the exacerbated hypercoagulability associated with increased concentrations of coagulation factors, acquired antiphospholipid antibodies, and reduced concentrations of endogenous anticoagulant proteins.

Patients with Covid 19 who develop more severe systemic inflammation and more critical respiratory function impairment are associated with a higher prevalence of thrombotic complications. Lodigiani et al reported 388 patients hospitalized with COVID-19 and a percentage of 16% of these with serious clinical conditions. Despite the use of low molecular weight heparin (LMWH) for thromboprophylaxis given to all patients in the ICU and 75% of those, not in the ICU, symptomatic VTE occurred in 4.4% of patients, ischemic stroke in 2.5%, and MI in 1.1% [55].
Given the knowledge we have, there is still no clarity on the extent to which SARS-CoV-2 increases the risk of thromboembolism. A study performed in the United Kingdom compared 1877 patients discharged from hospital after COVID-19 disease and 18 159 hospitalized for a non-COVID-19 disease reporting no difference in hospital-associated VTE rates (4.8 /1000 vs 3.1 /1000 ; odds ratio, 1.6 [95% CI, 0.77-3.1] ; P = .20) [56]. One point to clarify is whether the high rate of VTE is specific to patients who develop COVID-19 or if VTE is mainly occurring in patients with a major overall criticality of the disease and for the complications that arise.

### 2.2 Management of Thrombosis in Covid 19 patients

There are no international guidelines that direct the prevention and treatment of thrombotic complications in Covid-19 patients. Both published and ongoing studies testing interventions to prevent thrombosis complications in COVID-19 are based on the evidence reported in current clinical guidelines referencing VTE prophylaxis studies in acute n-COVID-19 medical disease. Therefore, pending the results to be provided by the completion of ongoing trials, guidelines for the treatment of thrombotic complications in patients with COVID-19 disease are derived from medical recommendations in the coagulation disorder populations (table).

However, the crucial point remains to be clarified whether these guidelines are also optimal for the treatment of thrombosis due to COVID-19.

Guidelines from the American College of Chest Physicians (ACCP) suggest the following prophylaxis with the administration of LMWH or fondaparinux rather than administration of unfractionated heparin or direct oral anticoagulants (DOACs) for all hospitalized patients with COVID-19 in the absence of contraindications, such as active bleeding episodes [57]. Clearly, the optimal choice of the drug to be adopted is constrained by the high contagiousness of Covid-19 disease and by the incomplete knowledge of the possible interference of SARS CoV2 with the drug. So, the 40mg dose of LMWH for injection once a day and the 2.5mg dose of fondaparinux 2.5mg are preferred over the administration of unfractionated heparin at a dosage of 2-3 times a day, limiting in the former options the doctor's contact with infected patients. In addition, these drugs are preferred over DOACs because of drug-drug interactions with antiviral agents.

Given the high incidence of VTE, the proposed therapeutic dose to be used for standard thromboprophylaxis in critically ill patients with Covid-19 was either double or single-dose administration of LMWH. The indications of the ACCP suggest the standard dose LWMH in the absence of new clinical trial data [57]. GDMT established by the International Society on Thrombosis and Hemostasis (ISTH) suggests administering half the therapeutic dose of LMWH (1 mg/kg per day) for prophylaxis in high-risk patients with COVID-19 while in patients with obesity the administration of a dose greater than 50%. However, it remains to be clarified which is the best dosage for optimal prophylactic therapy [58]. Ongoing randomized clinical trials to establish optimal antithrombotic prophylactic therapy are evaluating full dose administration for high-risk patients with COVID-19. Considering the pathophysiology of thromboembolism in COVID-19 characterized by platelet hyperreactivity, another point under discussion with RCTs initiated is the evaluation of administering an antiplatelet agent for therapeutic prophylaxis.

High-risk patients hospitalized for Covid 19 have a high possibility of developing VTE that persists after discharge [58]. However, for the latter, specific recommendations for post-discharge thromboprophylaxis established by the ACCP do not emerge[57]. In contrast, the ISTH recommendations for post-discharge thromboprophylaxis suggest the use of LMWH or a DOAC for all high-risk hospitalized patients with COVID-19 who have a low risk of bleeding.10 Patients with COVID-19 considered to be at high risk include those older than 65 years, presence of critical illness, cancer, previous VTE, thrombophilia, severe immobility,
and elevated D-dimer (> 2 times the upper limit of normal[58]). ISTH recommendations suggest a duration of 14 to 30 days for post-discharge thromboprophylaxis, although the ideal administration period remains to be clarified. For patients with Covid 19 disease, no diagnostic protocols have been established for thromboembolic complications, such as pulmonary embolism and MI, so the methods to be used should be those validated for patients without COVID-19. Given the lack of evidence to support the benefit, routine ultrasound checks for VTE surveillance are not recommended. For patients with COVID-19 diagnosed with arterial or venous thrombosis, the recommendations established by the current guidelines. These recognize the experienced benefits of LMWH administration in hospitalized patients while for outpatient setting DOAC administration is recommended [57]. There are currently no recommendations issued by ISTH and ACCP to support the validity of measuring the D-dimer to screen for VTE or to establish the intensity of prophylaxis or treatment [57].

3. COVID-19 Vaccines Administration vs Thrombosis and Variant. The new challenge

3.1. Nucleoside-Modified RNA encoding the SARS-CoV-2 Spike
Several studies have demonstrated the substantial role of the SARS-CoV-2 spike protein that binds to ACE2 receptors on target cells during viral entry. Studies performed on convalescent patients have highlighted the central role that the spike protein plays as immunodominant antigen supporting the host response, both antibody and T lymphocytes mediated[59]. Concerns about the rapid spread of the Covid 19 pandemic have favored the registration of numerous randomized clinical trials (RCTs) using different vaccination platforms in order to evaluate their efficacy and safety. Evidence has shown that the use of rapid response genetic platforms mRNA[60], adenoviral vector vaccines[61], inactivated viruses [62], and adjuvanted spike glycoprotein [63] resulted in neutralizing antibody responses after immunization.

The particular biological characteristics of mRNA synthesized in vitro may explain the superior efficacy of an ideal non-viral gene replacement tool leading to many intrinsic benefits 64. First, quick protein assembly and well-regulated primary cell transduction. Second, mRNA-based therapy avoids harmful side effects, such as its incorporation into the cellular genetic substrate, which can ultimately limit the clinical application of most virus- and DNA-based vectors [65]. Although, the use of in vivo gene transfer therapy has lived the first application almost twenty years ago [66]; however, its widespread usage as a vector for introducing genetic material into animals or even into cultured cells has been very limited. Indeed, the reports of Gilboa [67] and Pascolo[68] focused on the use of mRNA for vaccination purposes mainly directed at the development of cellular and humoral immune responses through antigen-encoding transcripts that were administered in vivo or delivered to dendritic cells (DC) ex vivo.

It should be noted that compared to gene replacement, RNA showed greater immunogenicity associated with less efficacy, to highlight an unfit role. Several studies conducted at the beginning of the year 2000 [69-72]have shown that RNA interferes with the cell-mediated immune response by activating the cells of the innate immune system. In particular, the action of the mRNA is directed towards the Toll-like receptors (TLR) and specifically for the cellular subgroups TLR3, TLR7, and TLR8.

Only 1 published study compared the in vitro immune response between nucleosides and modified nucleosides. The use of incorporated pseudouridine (Ψ), 5-methylcytidine (m5C), N6-methyladenosine (m6A), 5-methyluridine (m5U) or 2-thiouridine (s2U) in the transcript affected the immune response of most TLRs with a substantial loss of their activation[73]. Looking forward to testing nucleoside-modified mRNAs to evaluate their translation
potentials and immune characteristics in vivo, Hartamann et al [74] demonstrated that the 5'-triphosphate end of RNA produced by viral polymerases is accountable for retinoic acid-inducible protein I (RIG-I) -mediated detection of RNA molecules. Identification of 5'-triphosphate RNA is repealed by capping the 5'-triphosphate end or by nucleoside modification of RNA, including the use of s2U and Ψ.

The major implication of these findings led to in vitro transcripts containing nucleoside modifications not only translatable but also capable of activating an immune response in vivo. Therefore it was possible to subsequently develop mRNA with the function of a dual therapeutic tool for both gene replacement and vaccination. Evidence reported by Kariko et al [75,76]on the in vitro incorporation of pseudouridine, a modified nucleoside present in mRNA, has suggested that it not only suppress RNA-mediated immune activation in vitro and in vivo, but also improves RNA translation capacity.

3.2 RNA vaccine platform

In January 2020 the RNA sequence of the new coronavirus Sars Cov2 was introduced in the RNA vaccine platform so as to allow rapid development of the vaccine in response to the worsening spread of the pandemic. The advantages of vaccines that use RNA are manifold. They offer both greater flexibility during vaccine antigen design and expression and the ability to imitate viral antigen structure and expression during native infection. One of the characteristics that make them innovative is the lack of integration of viral RNA, which is necessary for protein synthesis, in the cell's genome. In fact, the viral genome is transiently expressed, it is metabolized and eliminated by the natural mechanisms of the organism, giving these vaccines greater safety[77-80]. As a rule, vaccination with RNA can stimulate a vigorous innate immune response eliciting B and T cell-dependent. RNA leads to the expression of the vaccine antigen in host cells and as demonstrated in specific mRNA vaccines against influenza A could address considerable medical demand in the area of influenza prophylaxis [81].

The immunogenic benefits associated with the in vivo administration of 1-methyl pseudouridine containing mRNA to induce high serum levels of interferon-α (IFN-α) were established in a landmark paper from Kariko et al.[75,76] The improved efficacy of nucleoside-modified RNA (modRNA) encoding the SARS-CoV-2 full-length spike modified by two proline mutations is almost certainly due to its superior immune response[11]. Studies conducted in the United States and Germany have reported substantially higher elicited SARS-CoV-2 neutralizing antibody titers and robust antigen-specific CD8+ and Th1-type CD4+ T-cell responses against nucleoside modified mRNA delivered in lipid nanoparticles [82-84].

There are two widely administered mRNA vaccines, BNT162b2 and mRNA-1273. Administration of a two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in phase 3 trial participants (n=21,720), aged 16 years and older (95% ; credible interval, 90.3 to 97.6). The group of participants assigned to receive BNT162b2 recorded 8 cases of Covid-19 disease with onset at least 7 days after the second dose while in the group of individuals assigned to placebo there were 162 cases of Covid 19 disease. Evidence observed from the analysis of subgroups defined by age, sex, race, ethnicity, baseline body mass index and the presence of coexisting conditions reported a similar efficacy of the vaccine with percentages between 90 and 100%. It is important to note that among 10 cases of severe Covid-19 with onset after administration of the first dose, 9 were reported in recipients the placebo dose and in 1 recipient the BNT162b2 dose. The safety profile of BNT162b2 was very high as evidenced by the short-term appearance of mild-to-moderate pain at the injection site, fatigue, and headache. The side effects were low and comparable to those recorded in the
placebo dose recipients. Furthermore, they were equivalent for a median of 2 months when comparing BNT162b2 with that of other viral vaccines[85].

Similar results were reported in phase 3 of the randomized, observer-blind, placebo-controlled trial after administration of mRNA-1273 (100 μg in 15,210 participants). The efficacy of the mRNA-1273 vaccine was recorded at 94.1% (95% CI, 89.3 to 96.8%; P<0.001) in the prevention of Covid 19 disease, including severe disease. Recipients of the double dose of mRNA-1273 were more than 96%, and only 2.2% had serological, virological, or both evidence of SARS-CoV-2 infection. Concern related to observed symptomatic Covid-19 disease was confirmed in 185 recipients of the placebo dose versus 11 recipients of mRNA-1273 dose.

Recipients of mRNA-1273 reported only transient local and systemic side effects and no safety concerns were recorded. A critical illness from Covid-19 occurred in the 30 recipients of the placebo dose with one death and in no participant who was administered the mRNA-1273.

It is important to clarify that current data on the messenger, derived from laboratory studies, have demonstrated the efficacy of RNA (mRNA) vaccines against SARS-CoV-2 variants. Researchers exposed serum samples from immunized individuals to genetically modified versions of related variants and then measured neutralizing antibody titers [86].

3.3 SARS-CoV-2 AND vaccine

We searched PubMed for research articles published by the launch of the database until April 30, 2021, indicating no language restrictions and using the terms "SARS-CoV-2", "vaccine", and "clinical trial". We identified published clinical trial data on seven SARS-CoV-2 studies and vaccines.

Four recombinant viral vectored vaccines have been tested in clinical trials. The vaccine ChAdOx1 nCoV-19 (AZD1222) was developed at the University of Oxford and is constituted with an adenoviral vector inactivated chimpanzee ChAdOx1 replication, containing the antigen glycoprotein gene structural surface SARS-CoV-2 (protein spike ; nCoV-19). This vaccine is one of the more extensively studied following the first UK Phase 1 clinical trial published on 23 April 2020. To date three more randomized controlled trials of the candidate vaccine have been initiated in the UK (COV002), Brazil (COV003), and South Africa (COV005). Recently a further phase 1/2 study was carried out in Kenya.

A pooled interim analysis of four trials (COV004) showed the safety and efficacy of the ChAdOx1 nCoV-19 vaccine. In recipients of two standard doses of ChAdOx1 nCoV-19, the vaccine efficacy was 62.1% and in recipients given a low dose followed by a standard dose, the efficacy was 90.0%. The overall efficacy of the vaccine after administration of both doses in the population studied was 70.4%. There were ten cases of COVID-19 that required hospitalization 21 days after the first dose and all in the control population. Two patients were in serious condition and one died. Authors recorded 175 serious adverse events that occurred in 168 participants, of which 84 events occurred in recipients of the ChAdOx1 nCoV-19 vaccine and 91 in the control group. Concern relating to clot formation or the occurrence of bleeding episodes has not been suggested across the analysis of 4 RCTs.

The immune response after vaccine administration in participants who received two doses of the vaccine was very effective. In particular, the specific objectives of phase 3 RCT were the evaluation of humoral and cellular safety and immunogenicity concerning both a single dose and two-dose regimen in adults over 55 years of age. Median anti-peak SARS-CoV-2 IgG responses 28 days after the boost dose were similar across the three age cohorts. Furthermore, neutralizing antibody titers after a boost dose were similar across age groups. Within 14 days of boost dose administration, a total of 208 of 209 (> 99%) recipients of the boosted dose of
ChAdOx1 nCoV-19 had neutralizing antibody responses. T cell responses peaked on day 14 following a standard single dose of ChAdOx1 nCoV-19. [87,88]

The Ad26.COV2.S vaccine is composed of a recombinant, replication-incompetent human adenovirus type 26 (Ad26) vector that encodes a full-length, membrane-bound SARS-CoV-2 spike protein in a prefusion-stabilized conformation [89-91]. At least 14 days after single-dose administration, Ad26.COV2.S conferred protection against both symptomatic Covid-19 infection and asymptomatic SARS-CoV-2 infection. The level of efficacy remained stable at 28 days after administration with an efficacy of 66.1% (adjusted 95% CI, 55.0 to 74.8). Covid 19 disease occurred in 66 recipients of the administration dose of Ad26.COV2.S compared to 193 for the placebo dose [92].

The results of the administration of Ad26.COV2.S vaccine has demonstrated efficacy against Covid 19 clinical disease with severe-critical manifestation, including hospitalization and death. Evidence suggested a high level of efficacy after administration of Ad26.COV2, which was greater against severe Covid-19 disease and reached a rate of 76.7% for onset at ≥14 days [adjusted 95% CI, from 54.6 at 89.1]. At 28 days in participants receiving the single dose the reported efficacy was 85.4% [adjusted 95% CI, 54.2 to 96.9] for onset at ≥28 days. However, the unexpected data were related to the immunogenic response to Ad26.COV2 vaccine against the South African variant 20H / 501Y.V2. 86 out of 91 cases (94.5%) of patients with moderate to severe-critical Covid-19, in which the virus variant was sequenced, showed vaccine efficacy that reached 52.0% and 64.0% with onset of at least 14 days and at least 28 days after dosing, respectively. The efficacy against severe critical Covid-19 disease reached 73.1% and 81.7% at 14 days and 28 days respectively after the single dose of Ad26.COV2.

Evidence supported a level of safety comparable to that of other Covid-19 vaccines that progressed phase 3 studies. Although the reactogenicity was greater with the administration of Ad26.COV2.S compared to the placebo dosage; however, it was generally mild to moderate and transient. Note that the incidence of severe adverse events was recorded alike among the two populations of participants with three deaths occurring in the vaccine group. No episodes attributable to thrombotic or haemorrhagic phenomena have been reported.

Vector-based adenovirus (Ad) 5 (CanSino Biological / Beijing Institute of Biotechnology, China[93]) was administered in a single dose and resulted in the production of neutralizing antibodies which increased significantly on day 14 and peaked 28 days after vaccination. A specific T-cell response in a dose-dependent manner peaked at day 14 after vaccination. However, of note that the vaccine demonstrated lower immunogenicity in participants over the age of 55. Administration of adenovirus type-5 vectored COVID-19 recorded no serious adverse event within 28 days post-vaccination. An equal rate of side effects was reported in the three groups studied. Reactogenicity was evident in the first 7 days after administration in 30 (83%) recipients of a low dose vaccine, in 30 (83%) recipients of a medium dose, and in 27 (75%) recipients of a high dose, respectively.

A heterologous recombinant adenovirus (rAd26 and rAd5)-based vaccine, Gam-COVID-Vac (Sputnik V[94]) showed efficacy and safety from the interim analysis of phase 3 RCT. The characteristic of Gam-COVID-Vac is that of being a combined vector vaccine because it consists of rAd type 26 (rAd26) and rAd type 5 (rAd5). Both adenoviruses carry the gene for the SARS-CoV-2 full-length glycoprotein S (rAd26-S and rAd5-S). The administration of rAd26-S and rAd5-S is carried out intramuscularly separately with an interval of 21 days. The results of the Phase 1/2 clinical trials showed that the Gam-COVID-Vac vaccine was well tolerated and highly immunogenic in healthy participants. Vaccine efficacy of Gam-COVID-Vac reached 91.6% (95% CI 85.6–95.2) with few tolerable side effects graded as 1 (7485 [94.0%] of 7966 total events). Although 45 (0.3%) of recipients of this vaccine (n=16 427) and 23 (0.4%) of recipients of the placebo dose recorded serious adverse events; however
none were accounted associated with vaccination. There were four deaths during the study.
Three (<0.1% of a total of 16 427) were participants from the vaccinated population and one
(0 · 1% of the total of 5435) received a placebo. None of these deaths were considered
related to the vaccine.
Chinese researchers worked on two inactivated viral vaccines [95,96]. Two SinoPharm
vaccines have shown neutralising antibody responses. Participants the administration of the
first SinoPharm vaccine (Wuhan Institute Biological Products/SinoPharm, China) the immune
response was in a dose-dependent manner in adults aged 18–59 years. The second SinoPharm
product (Beijing Institute Biological products/SinoPharm, China) elicited neutralizing
antibody response in adults aged 18–59 and 60 years and older. In addition, the latter showed
lower neutralising antibody titres in older adults after two doses.
Finally, a clinical study of a vaccine assembling nanoparticles consisting of adjuvanted
trimeric spike glycoproteins from severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) (Novavax, USA) recorded preliminary results. The vaccination schedule included the
administration of two doses 3 weeks apart in healthy adults less than 60 years of age.
Evidence suggested good tolerance for this vaccine which induced neutralisation responses
greater than those measured in serum samples from convalescent symptomatic patients [97].

Vaccines and immunogenicity against genetic variants

With the spread all over the world of the genetic variants of SARS-CoV2 and the intersection
of the number of cases of Covid 19 disease, the most recurring question today is the real
effectiveness of the vaccines currently administered on the mutated virus. Concern related to
less immunogenicity of vaccines emerged at the end of January simultaneously with the
strong spread of B.1.351 and arises from working with a fixed immunogen but with the
mutating virus.[98].

This restlessness is fueled by the mutagenic potential of SARS-CoV-2, which can lead to
mutations in a global context where vaccination progresses at different rates. Since viruses
copy themselves by repeating sequences and making mistakes all the time, the possibility that
they mutate is very frequent. Despite the many mistakes that viruses can make by replicating
we are not aware of any vaccine against viral diseases, other than seasonal influenza, which
has required an update on the basic constitution due to changes in the virus genome. For
example, despite the frequent mutations recorded by the hepatitis B virus, it does not escape
the action of the vaccine, guaranteeing safety and efficacy in the population.
A large part of the world population in low-middle-income countries can be considered
excluded from mass vaccination programs. In addition, the progression of vaccination records
different trends in high-income countries. The principle according to which persistent
infections and viral replication give the virus the possibility of mutating the genome with a
high frequency must make us reflect on the need to homogeneously extend the administration
of vaccines without any distinction.

3.3 Current knowledge

Although the term vaccine resistance has been used by experts in the field to describe the
reduced efficacy of COVID-19 vaccines against some variants; however this term can cause
inaccuracies. In fact, more commonly the concept of drug resistance is aimed at antibiotics
that are taken by people. In the case of vaccines, the administration has not taken place, so the
person cannot be resistant but can have a reduced immune response.

Vaccines administered against COVID-19 are engineered from the SARS-CoV-2 spike
protein of the original virus called Wuhan-hu-1 [99]and used by the virus to bind and infect
host cells. Emerging data from Covid 19 disease suggests that variants of the "parent" virus
appear to be more transmissible or more lethal than Wuhan-hu-1 and may contain mutations in the spike protein causing for vaccine efficacy problems.

All of the randomized controlled trials evaluating Pfizer-BioNTech and Moderna vaccines, the first to be cleared by the FDA, were conducted primarily in the United States before any cases of infection attributable to variant B.1.351 or others emerged, raising the problem of the reduction of efficacy of Pfizer-BioNTech and Moderna in the USA[100-104].

Regarding viral vector vaccines or the vaccine that uses a nanoparticle, the evidence provided by the RCTs of Novavax[105], Janssen / Johnson & Johnson, and AstraZeneca in South Africa, where variant B.1.351 is widespread, have raised a veil of uncertainty about the effectiveness of vaccines. The concern is related to the fact that since variant B.1.351 represents practically all the SARS-CoV-2 circulation in South Africa, a reduction in the efficacy of these vaccines has been recorded in comparison to other countries where the variant was not dominant.

Conclusive data did not emerge in current literature with a constant update of the findings. Scientists working on the efficacy of mRNA vaccines have produced evidence against the SARS-CoV-2 variants that are derived from laboratory studies. Researchers tested the serum of people immunized to the modified in protein spike variant of the virus and subsequently measured the antibody titers produced. Such studies have constantly reported that vaccines arose lower levels of neutralizing antibodies against the SARS-CoV-2 variants than the antibody titer that was produced against the older and more common variants.

In one study[106] serum samples, individuals immunized with 2 doses of Pfizer-BioNTech vaccine were evaluated and tested against the recombinant virus which contained S-glycoprotein mutations similar to those found in variant B.1.351. The authors found that the neutralisation of B.1.351 was approximately two-thirds lower than the mutation in the USA-WA1 / 2020 variant, one of the earliest variants of the SARS-CoV-2 "parent" virus.

Another report [107] measured neutralisation antibody activity using serum samples of recipients of the mRNA-1273 Moderna vaccine and belonging to phase 1 of the trial. One week after the individuals received the second dose of mRNA-1273 Moderna vaccine, neutralizing antibody titers induced by a recombinant virus bearing the B.1.351 spike protein were 6-fold lower than those induced by a recombinant virus bearing the original Wuhan-Hu-1 spike protein. However, the elicited antibody response may still be sufficient to protect against COVID-19, or at least the more severe forms of COVID-19.

3.4 Immunogenicity and variants. Where the effectiveness of vaccines ends

To date, optimal antibody protection levels have not yet been determined for SARS-CoV-2 infection. The favorable data concern the immune cell response mediated by virus specific helper T cells and cytotoxic T cells induced by mRNA vaccines which in addition to neutralized antibodies, counteracts the infection [108].

Today we do not have immune correlates of protection against the variants of SARS CoV2 and only the massive administration of vaccines in the population will be able to provide evidence if they are effective in preventing disease and the contagion of the infection caused by the variants. As of today, we only know the efficacy of selected vaccines and for selected cases. (Table 1)
Table 1. Efficacies of Covid-19 vaccines are compared according to disease and infection prevention. Highlighted are efficacies exceeding the 75% of potency which we set as a point of comparison between them. Some variables are estimations available from literature studies (UK SIREN study). The general source is IHME- Institute for Health Metrics and Evaluation documents on data summaries. Data are updated until April 26, 2021.  

| Anti-SARS-CoV-2 vaccine type | Efficacy at preventing disease (D614G and B.1.1.7.) | Efficacy at preventing infection (D614G and B.1.1.7.) |
|-----------------------------|----------------------------------------------------|----------------------------------------------------|
| BNT162b2                    | 91%                                                | 86%                                                |
| mRNA-1273 (Moderna)         | 94%                                                | 85%                                                |
| ChAdOx-1 nCov-2             | 75%                                                | 52%                                                |
| Ad26.COV2-S (Janssen)       | 72%                                                | 72%                                                |
| CoronaVac (Sinovac)         | 50%                                                | 43%                                                |
| Sputnik V                   | 92%                                                | 80%                                                |
| Novavax                     | 89%                                                | 77%                                                |
| Sinopharm                   | 73%                                                | 63%                                                |
| Tianjin CanSino             | 66%                                                | 57%                                                |

Indeed, the opposite has happened. Individuals who had been vaccinated were hospitalized because they had Covid 19 for infection caused by the mutated virus [109].

A frustrating situation is suggested by the discouraging results from the Phase 2 trials of the Oxford-AstraZeneca vaccine administered in South Africa. In the study participants it was recorded that the vaccine did not protect mild to moderate COVID-19 disease caused by variant B.1.351[110]. Following the findings, the vaccination schedule based on the administration of AstraZeneca was modified[111]. Analyzing this report it emerges that it was not designed to determine if the vaccine leads to protection against severe forms of Covid 19 or not. A potential bias was the number of participants (n=2000) who were young, mean age 31, who were healthy and at low risk of developing severe Covid 19 disease regardless of inclusion in the vaccine or non-vaccine group.

Studies by Novavax and Janssen have provided more evidence from the administration of the corresponding vaccines in South Africa than the Oxford vaccine /AstraZeneca. [112,113] Although the results demonstrate lower efficacy rates for Novavax and Janssen in participants enrolled in randomized controlled trials in South Africa compared to studies in other countries. For example, the phase 3 results in recipients of the Janssen vaccine showed that the likelihood of being hospitalized for a severe form of COVID-19 was lower than those who received the placebo dose. The phase 3 results of the Novavax vaccine RCT, not yet published, could point in the same direction.

The reference point for an analysis of the real situation on the progression of COVID-19, both in reference to the spread of the infection / number of cases and the need for hospitalization or intensive care, is the state of Israel[114] but the Buthan state has been a case study for the low viral diffusion. As of May 11, 2021 the World Health Organization WHO reports 20 new cases per day, 1241 total cases (PCR-positive Covid-19 patients, both symptomatic and asymptomatic) and 1 death.

In Israel, the number of Covid 19 patients began to decline in mid-January in the country which is the world leader in percentage of the population vaccinated.

The effects of the mass vaccination program are evident in the drastic reduction in the need for hospitalization for older individuals, with a reduction in the absolute number of infections, which were the highest category with absolute priority for vaccination [115].
An analysis of the hospitalization trend shows that in one week the percentage of patients requiring hospitalization for a severe form of Covid 19 decreased from 36% to 29%, compared to the previous 3 weeks. As variant B.1.1.7, first isolated in the UK, is now the dominant variant of SARS-CoV-2 in Israel as well as in the United Kingdom it is evident that this variant does not seem to influence the production of neutralizing antibodies after the administration of the Pfitzer Biointech vaccine to the same extent as it did for B.1.351[115].

The same outcomes were recorded from a report performed in the United Kingdom in which researchers compared the Pﬁzer-BioNT and Oxford-AstraZeneca vaccines. They demonstrated that the latter achieved efﬁcacy in preventing Covid 19 disease in 94% of recipients compared to 85% of Pﬁzer-BioNT vaccine recipients. Hospital admissions were therefore reduced in the 28-34 days after a single dose. The results of this study suggest a postponement of the administration of the second dose after 12 weeks[116].

Generally, human vaccines have the characteristic of reducing the manifestations of the disease and in general also the transmission. This peculiarity has not yet been fully demonstrated for vaccines against Covid 19. Therefore another criticality could be represented by vaccinated individuals infected by the variants but asymptomatic which represent an adequate reservoir of contagion and diffusion of the variants. In fact the increased risk of these individuals lies in the fact that the absence of the manifestation of the symptom does not prevent the spread of the infection because they are capable of infecting unvaccinated individuals.

Recent evidence suggests a reduction in transmission. A study evaluated viral transmission in healthcare professionals. Individuals immunized with the Pﬁzer-BioNTech vaccine were subjected to controls with 1 PCR test and two rapid tests to identify the percentage of infected individuals in the two populations of asymptomatic and symptomatic. The results revealed a 70% reduction in infection in the two populations after 21 days from the administration of the first dose of vaccine and an 85% reduction after administration of the second dose [117]. These could be supported by a Pﬁzer-BioNTech-sponsored study not yet peer-reviewed in which the vaccine was 94% effective in asymptomatic SARS-CoV-2 infection [118,119].

The most heated debate concerns whether for COVID-19 there will be the same periodicity in the vaccination as in the case of inﬂuenza with the difference that for the latter, despite being an infectious disease, vaccination is not mandatory. Undoubtedly, mRNA-based technology opens up new possibilities such as creating a vaccine that protects against most variants of SARS CoV2.

The biggest challenge appears to be to make enough changes to the mRNA platform vaccines to address the emerging variants. Pfizer and BioNTech have opened the possibility of administering a third dose of the vaccine BNT162b2 to increase immunological activity, to confer greater safety and efﬁcacy against SARS-CoV-2 variants. One study was designed to make speciﬁc changes to BNT162b2 directed speciﬁcally against variant B.1.351[120].

Modiﬁcations of mRNA-1273 with a booster dose for variant B.1.351 are under study [121]. Inherently to Novavax vaccine, the ﬁrst generation of which has not yet been authorized in the United States, scientists are working on a booster dose or a bivalent combination vaccine, to increase the degree of protection from variants[122]. Recently the NVX-CoV2373 vaccine was eﬁcacious in preventing Covid-19 disease, with manifestations of the disease of mild to moderate degree due to the B.1.351 variant [122].

The main challenge today lies in conducting studies comparing the degree of production of neutralizing antibodies against SARS CoV2 elicited by prototype vaccines and engineered on the Wuhan-hu-1 variant from elicited antibody responses against the new variants of SARS CoV2. In another study, scientists could use serum samples from people previously vaccinated with a prototype vaccine who are given an experimental booster dose against the more contagious variants. (ﬁgures 1,2)
Figure 1. SARS-CoV-2 variants and the respective efficacy by most administered vaccines is shown [123]. B.1.1.7, i.e. the UK variant has been recently studied by investigators: 89.5% and 74.6% efficacy have been demonstrated against the variants by the ChadOx-1 nCoV-19 respectively. Percentages of efficacy from the other vaccines versus the main variants of concern (VOC) are also presented. Numbers mainly reflect efficacies against the symptomatic non-severe infection by SARS-CoV-2. Spike protein mutations are pictured on the side of each variant which they belong to [123].

Figure 2. Variants of Interest (VOI) are illustrated. Every box reflects a country the first variant was discovered in. As for variants of concern, the Spike protein mutations associated with the variant is displayed. Efficacy of vaccines has not been reported due to the lack of data in terms of both literature studies and official national reports. Data are updated until May 6, 2021 [124].

3.5 SARS-CoV-2 adenoviral vector vaccines and the risk to develop thrombosis
SARS-CoV-2 vaccines were reported as safe and effective before their marketing and worldwide distribution by first, second, third phase clinical trials and pooled analyses.
During February 2021, large-scale epidemiological data started to rise, suspects of coagulopathies, after adenoviral vector-based vaccines reached millions of administered doses both in Europe and United States. In particular, the ChAdOx1 nCov-19, marketed by company AstraZeneca and subsequently renamed Vaxzevria vaccine, has been considered responsible for the development of arterial and venous thromboembolism in a selected population, mostly of the female sex, under the age of 60 years.

A single dose (0.5 mL) of the vaccine has been formulated to contain about $2.5 \times 10^8$ infectious units (Inf.U) of Chimpanzee Adenovirus encoding the SARS-CoV-2 Spike glycoprotein (ChAdOx1-S).

The generation of the final product derives from the genetically modified human embryonic kidney (HEK) 293 cells. Recombinant DNA technology was also used for this intent [125].

Despite being those rare events, around 1 in 100 000 recipients, further considerations are warranted and did justify European Medical Agency EMA accuracy in examining those cases.

In April 2021, Greinacher et al [126] reported 11 cases of thrombosis, among which 10 multiple ones, involving cerebral and splanchnic veins with one death. Pulmonary embolisms PE were also frequent in this subset of patients. Nonetheless, conditions that required medical treatment included disseminated intravascular coagulation DIC and suspected strong thrombocytopenia. The etiology has not been fully understood but it has become clear that antibodies anti-platelet factor 4 PF4 in those patients serum were considered implicated and played a fundamental role in what was initially described as similar to the heparin-induced thrombocytopenia HIT, with the difference that heparin was not administered in all cases and antibodies binding was successful even in the absence of heparin.

Surely, immune mechanisms drove the syndrome escalation which was named VITT (vaccine-induced thrombotic thrombocytopenia).

Of note is the time of development of the first symptoms, with an average of 1-2 weeks after the administration of the first dose. This is the reason why European governments started to reassure the population who already underwent the first dose of the ChAdOx1 nCov-19 vaccine to also receive the second one if no side effects were reported.

Schutlz et al.[127] also published clinical cases of patients, mostly women, presenting with venous thrombosis of which 2 sigmoid cerebral sinuses thromboses, a portal vein branches' thrombosis, cerebral vein thrombosis, and a complication of right cerebellar haemorrhagic infarction. In all of those cases, antibodies anti-PF4 were identified in patients' plasma.

3.6 SARS-CoV-2 vaccine-induced thrombotic thrombocytopenia
Platelet factor 4 (PF4) is a platelet-derived cytokine of the CXC family. It is released by activated platelets to promote coagulation via neutralization of heparin-like molecules on endothelial cells. In concert with polyanionic PGs derived from endothelial cells, they create complexes autoantibodies direct to.

They have been identified by enzyme-linked immunosorbent assay (ELISA) and assays based on platelet activation, which, when tested, was enhanced by the addition of PF4. Thus, IgGs were found responsible for directly stimulation coagulation via FcγRIIA receptor-dependent mechanisms.

Goldman et al.[128] recently proposed a model according to which the first activation of platelets may lead to PF4 released in the circulation. In turn, complexing with polyanionic
prostaglandins PGs, stimulate extrafollicular B cells to produce anti-PF4 IgGs. From this point, the molecular consequently clinical effects would then resemble heparin-induced thrombocytopenia HIT ones. (Figure 3)

**Figure 3.** The proposed mechanism of autoantibodies generation is described. Following administration of adenoviral vector encoding the spike protein, a subsequent inflammatory cascade, stimulated by the individual immune response, activates platelets to generate platelet-factor 4 PF4. In complexes with polyanionic PGs, derived from endothelial cells, they stimulate extrafollicular B cells to antibody production which, in turn, would exert positive feedback on platelet activation. They would resemble HIT autoantibodies from that point on with respect to thrombogenesis and hemostasis disorders.

PF4 shares some epitopes with the Spike protein but, despite this, they are not sufficient to induce cross-reactivity. PF4: platelet factor 4, HIT: heparin-induced thrombocytopenia, PGs: proteoglycans.

Interestingly, investigators have discarded the hypothesis of molecular mimicry mechanisms, due to the absence of cross-reaction with SARS-CoV-2 derived Spike protein [126]. The authors analyzed the Spike protein sequence and found 3 similar immunogenic epitopes with PF4. In particular, prediction tools and 3D modeling software among which IMED and SIM were used to compare them. Subsequently, they collected blood sera from 222 patients which tested positive for PCR analysis of SARS-CoV-2 infection and tested them for the presence of PF4/heparin ELISA, heparin-dependent, and PF4-dependent platelet activation assays [126].

Results are reinforcing the hypothesis that the Spike protein is not inducing VITT: only 19 of 222 patients tested positive for PF4/heparin ELISA but those patients did not show any platelet hyperactivation sign. Furthermore, anti-PF4 and anti-PF4/heparin antibodies from two VITT patients were tested. They did not show any cross-reactivity to the recombinant SARS-CoV-2 spike protein [126].

The same research group from Greinacher et al. NEJM had been studying the mechanisms underlying autoimmunity of HIT and not only [129]. By examining the binding forces expressed as pN (picoNewton) which are applied by antibodies in their binding to the target, they found substantial differences in terms of platelet activation. In particular, they divided groups of antibodies according to classes of force:

- Antibodies binding with a force of 60–100 pN were found to activate platelets in the presence of polyanions, while, in their absence, some antibodies from autoimmune-HIT patients with binding forces Z100 pN were binding to PF4 [129].
Therefore, those higher forces were able to cluster PF4-molecules forming antigenic complexes which allow binding of polyanion-dependent anti-PF4/P-antibodies. That induced massive platelet activation in the absence of heparin.\textsuperscript{[129]}

3.7 Public health challenges: do benefits outweigh risks?
Since the first cases of thrombosis for the ChAdOx1 nCoV-19 vaccine were reported, several studies tried to compare the incidence of those events with that of the general population\textsuperscript{[130]}.

Pottegard and colleagues\textsuperscript{[131]} assessed rates of hemostatic events in a cohort of 148792 vaccinated population from Denmark and compared them with general population cohorts from Denmark and Norway. Results showed 59 venous thromboembolic events in the vaccinated cohort compared with 30 expected based on general incidence rates.

In particular, higher rates of cerebral venous thrombosis were observed: the standardised morbidity ratio for it was demonstrated to be 20.25 (8.14 to 41.73). Interestingly, the rate of death was superior for the general population: 44 cases versus 15 for the vaccinated group\textsuperscript{[131]}.

Increased surveillance of them could justify these numbers and prove the beneficial effects of ChadOx1 vaccine outweigh the risks.

Notably, the European Medicines Agency (EMA) started to investigate thrombotic events through the Pharmacovigilance Risk Assessment Committee (PRAC) to review all those conditions, among which thrombocytopenia and bleeding too, are related to haemostatic alterations after vaccines administration\textsuperscript{[132]}.

According to the pharmacovigilance legislation, additional monitoring is mentioned with a label on the package whenever it is needed. Furthermore, the medical literature is continuously monitored by EMA to guarantee suspect adverse reactions to be correctly addressed.

Thus, the status under which vaccines have been put by EMA is "conditional marketing, authorization granted". This is true for Vaxzevria, Moderna, Janssen, and Comirnaty vaccines\textsuperscript{[132]}.

3.8 Updates from the European Medicines Agency
By May 7, 2021, the PRAC committee has put under evaluation more suspected reports of hemostatic and non-hemostatic conditions in other anti-Covid-19 vaccines\textsuperscript{[133]}.

Myocarditis and pericarditis cases have been associated, even though causative link has never been proved, to Comirnaty (BNT162b2) vaccination. EMA has requested analyses of data and marketing authorization holders for both Comirnaty and Moderna. Recent investigations are interesting cases of Guillan-Barré syndrome after vaccination with the Vaxzevria vaccine. Further detailed monitoring is necessary.

Some cases of thrombocytopenia have been reported for mRNA vaccines too, in particular Comirnaty and Moderna vaccines. Epidemiological studies are confirming the rate of those cases is lower than the general population incidence rate\textsuperscript{[133]}.

The BNT162b2 vaccine has been subject of EMA evaluations also for cases of facial swelling in people with a history of injections with dermal fillers. PRAC committee has decided to validate this adverse effect by inserting it in the Comirnaty's product information. This has been possible thanks to literature revision and European database for suspected side effects EudraVigilance\textsuperscript{[133]}.
3.9 Janssen adenoviral vector vaccine and cases of thrombosis

The Ad26.COV2.S vaccine has been associated with cases of cerebral venous sinus thrombosis (CVST), severe thrombocytopenia, and disseminated intravascular coagulation. In total, 6 cases of thrombosis were reported occurring 7 to 14 days after vaccination.

The case described by Muir et al\textsuperscript{[134]} is interesting since the patients showed signs of autoimmune heparin-induced thrombocytopenia. The patient, 48-year-olds, of female gender presented with general malaise and abdominal pain. From peripheral blood tests, thrombocytopenia with schistocytes at the blood smear was revealed. Coagulation tests also confirmed low fibrinogen level, prolonged activated partial thromboplastin time, and an elevation in the D-dimer level. Factor V Leiden and Prothrombin G20210A gene mutation were negative. Also, hepatitis, HIV, and Lupus were tested but later ruled out. Investigators concluded the diagnostic workup with a Computed tomographic (CT) scan of the abdomen and pelvis demonstrated massive splanchnic veins thrombosis and cerebral CT scan revealed, after the new-onset headache of the patient, cerebral venous sinus thrombosis involving the right transverse and straight sinuses.

The patient was further tested for anti-PF4-heparin antibodies but resulted negative, even because she was previously treated with unfractionated heparin. When evaluated for anti-PF4-polyanions antibodies, the patient tested positive (2.550 optical-density units [upper limit of the normal range, \(\leq 0.399\)). She was therefore switched to therapy with argatroban.

Thus, the case of thrombosis described by Muir et al\textsuperscript{f} demonstrates an update in literature reports associated with the ChAdOx1 nCoV-19 but several authors, including Sadoff et al\textsuperscript{[135]}, concluded that the Janssen vaccine and Vaxzevria one, despite sharing some common features have different intrinsic structures.

Notably, the Ad26.COV2.S vaccine is composed of a human Ad26–based vector and Ad26 is from Ad species D. Its cellular receptor, differently from the ChAdOx nCoV-19 vaccine which uses the Coxsackie and adenovirus receptor (CAR), is CD46.

The ChAdOx1 nCoV-19 vaccine is a chimpanzee adenovirus-based vector and Ad26 is from Ad species E. Thus, their biological characteristics are strongly different, even though the mechanism of immunologic response in the host is similar.

Conclusions

The SARS-CoV-2 infection has highlighted the importance of preventative medicine. The systemic effects of this are still relatively poorly understood, but several risk factors have been identified. The roll-out of the vaccines worldwide has also allowed the lifting of lockdown measures and a reduction in the spread of the disease. Ongoing epidemiological research is needed to monitor the variant strains and ascertain the ongoing efficacy of the vaccine against the virus.

Financial support: None
Conflict of interest Statement: None
References

1. Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060-2072. doi:10.1016/j.jacc.2020.08.070

2. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–7.

3. Bikdeli B, Madhavan MV, Jimenez D, et al., for the Global COVID-19 Thrombosis Collaborative Group. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2950–73.

4. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, healthcare workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020;75:2352–71.

5. Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol 2020;5:751–3.

6. Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med. 2020;8(7):681-686. doi:10.1016/S2213-2600(20)30243-5

7. Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 2020;173:268–77.

8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.

9. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;18:1421-4

10. Allard, J., Dushek, O., Coombs, D., van der Merwe, P. 2012. Mechanical modulation of receptor-ligand interactions at cell-cell interfaces. Biophys. J. 102, 1–9.

11. Mary, S., Fehrentz, J., Damian, M., Vedić, P., Martinez, J., Marie, K., Baneres, J., 2013. How ligands and signaling proteins affect G-protein-coupled receptors’ conformational landscape. Biochem. Soc. Trans. 41, 144–147.

12. Unal, H., Karnik, S., 2012. Domain coupling in GPCRs: the engine for induced conformational changes. Trends Pharmacol. Sci. 33 (2), 79–88.

13. Kobilka, B., Deupi, X., 2007. Conformational complexity of G-protein-coupled receptors. Trends Pharmacol. Sci. 28 (8), 397–406.

14. Lefkowitz, R., 2007. Seven transmembrane receptors: something old, something new. Acta Phys. 190, 9–19.

15. Lu, Y., Liu, D.X., Tam, J.P., 2008. Lipid rafts are involved in SARS-CoV entry into vero E6 cells. Biochem. Biophys. Res. Commun. 369 (2), 344–349.

16. Oates, J., Watts, A., 2011. Uncovering the intimate relationship between lipids, cholesterol and GPCR activation. Curr. Opin. Struct. Biol. 21, 1–6.

17. Shukla, A. (Ed.), G Protein-Coupled Receptors. Signaling, Trafficking and Regulation. Methods in Cell Biology, vol. 132, 1st ed.. Elsevier
18. Villar, V., Cuevas, S., Zheng, X., Jose, P., 2016. Chapter 1: localization and signaling of GPCRs in lipid rafts. Methods Cell Biol. 136, 3–23.

19. Watkins, E., Miller, C., Majewski, J., Kuhl, T., 2011. Membrane texture induced by specific protein binding and receptor clustering: active roles for lipids in cellular function. Proc. Natl. Acad. Sci. 108 (17), 6975–6980.

20. Lu, Y., Liu, D.X., Tam, J.P., 2008. Lipid rafts are involved in SARS-CoV entry into vero E6 cells. Biochem. Biophys. Res. Commun. 369 (2), 344–349.

21. Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020;136(11):1347-1350. doi:10.1182/blood.2020008086

22. Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454.

23. Li, W.; Zhang, C.; Sui, J.; Kuhn, J.H.; Moore, M.J.; Luo, S.; Wong, S.K.; Huang, I.C.; Xu, K.; Vasilieva, N.; et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005, 24, 1634–1643.

24. Li, W.; Zhang, C.; Sui, J.; Kuhn, J.H.; Moore, M.J.; Luo, S.; Wong, S.K.; Huang, I.C.; Xu, K.; Vasilieva, N.; et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005, 24, 1634–1643.

25. Wu, K.; Peng, G.; Wilken, M.; Geraghty, R.J.; Li, F. Mechanisms of host receptor adaptation by SARS coronavirus. J. Biol. Chem. 2012, 287, 8904–8911.

26. Ren, W.; Qu, X.; Li, W.; Han, Z.; Yu, M.; Zhou, P.; Zhang, S.Y.; Wang, L.F.; Deng, H.; Shi, Z. Difference in receptor usage between severe acute respiratory syndrome (SARS) coronavirus and SARS-like coronavirus of bat origin. J. Virol. 2008, 82, 1899–1907.

27. Menachery VD, Yount BL Jr, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015 Dec;21(12):1508-13

28. Menachery VD, Yount BL Jr, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge XY, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi ZL, Baric RS. Author Correction: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2020 Jul;26(7):1146

29. Ge, X.Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).

30. Jeffers, S.A.; Tusell, S.M.; Gillim-Ross, L.; Hemmila, E.M.; Achenbach, J.E.; Babcock, G.J.; Thomas, W.D.; Thackray, L.B.; Young, M.D.; Mason, R.J.; et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 15748–15753.
31. Jeffers, S.A.; Hemmila, E.M.; Holmes, K.V. Human coronavirus 229E can use CD209L (L-SIGN) to enter cells. Adv. Exp. Med. Biol. 2006, 581, 265–269.

32. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11 (8):875-879. doi:10.1038/nm1267

33. Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Accessed March 22, 2020. https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-reusing-RAAS-antagonists-in-COVID-19.jsp?utm_campaign=sciencenews19-20&utm_source=science-news&utm_medium=email&utm_content=phd03-17-20

34. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11 (8):875-879. doi:10.1038/nm1267

35. Xie X, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166-2171. Published correction appears in Life Sci. 2006;79(26):2499. doi:10.1016/j.lfs.2005.09.038

36. Lakatta EG. The reality of getting old. Nat Rev Cardiol. 2018;15(9):499-500. doi:10.1038/s41569-018-0068-y

37. Liang W, Zhu Z, Guo J, et al; Beijing Joint SARS Expert Group. Severe acute respiratory syndrome, Beijing, 2003. Emerg Infect Dis. 2004;10(1):25-31. doi:10.3201/eid1001.030553

38. Backhaus A. Coronavirus: why it’s so deadly in Italy. Accessed March 22, 2020. https://medium.com/@andreasbackhausab/coronavirus-why-its-so-deadly-in-italy-c4200a15a7bf

39. Imai Y, Kuba K, Rao S, et al. Angiotensin converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-116. doi: 10.1038/nature03712

40. Wang D, Chai XQ, Magnussen CG, et al. Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation. Pulm Pharmacol Ther. 2019;58:101833. doi:10.1016/j.pupt.2019.101833

41. Fallahi-Sichani, M., Linderman, J., 2009. Lipid raft-mediated regulation of G-protein coupled receptor signaling by ligands which influence receptor dimerization: a computational study. PLoS ONE 4 (8), e6604.

42. Tetlow S, Segiet-Swiecicka A, O'Sullivan R, O'Halloran S, Kalb K, Brathwaite-Shirley C, Alger L, Ankuli A, Baig MS, Catmur F, Chan T, Dudley D, Fisher J, Iqbal MU, Puczynska J, Wilkins R, Bygate R, Roberts P. ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. J Intern Med. 2021 May;289(5):688-699. doi: 10.1111/joim.13202.

43. Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, Viggiani G, Panico C, Regazzoli D, Ciccarelli M, Voza A, Aghemo A, Li H, Wang Y, Condorelli G, Stefanini GG. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020 Nov 1;6(6):412-414. doi: 10.1093/ehjcvp/pvaa056.
44. Derington CG, Cohen JB, Mohanty AF, Greene TH, Cook J, Ying J, Wei G, Herrick JS, Stevens VW, Jones BE, Wang L, Zheutlin AR, South AM, Hanff TC, Smith SM, Cooper-DeHoff RM, King JB, Alexander GC, Berlowitz DR, Ahmad FS, Penrod MJ, Hess R, Conroy MB, Fang JC, Rubin MA, Beddu S, Cheung AK, Xian W, Weintraub WS, Bress AP. Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans. PLoS One. 2021 Apr 23;16(4):e0248080. doi: 10.1371/journal.pone.0248080.

45. Parit R, Jayavel S. Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study. Eur J Pharmacol. 2021 Apr 5;896:173899. doi: 10.1016/j.ejphar.2021.173899.

46. Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020;8(4):e21.

47. Watkins J. Preventing a covid-19 pandemic. BMJ. 2020;368:m810. doi: 10.1136/bmj.m810

48. Abuohashish H.M., Ahmed M.M., Sabry D., Khattab M.M., Al-Rejaie S.S. ACE-2/Ang1-7/Mas cascade mediates ACE inhibitor, captopril, protective effects in estrogen-deficient osteoporotic rats. Biomed. Pharmacother. 2017;92:58–68. doi: 10.1016/j.biopha.2017.05.062.

49. Saponaro F, Rutigliano G, Sestito S, Bandini L, Storti B, Bizzarri R, Zucchi R. ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives. Front Mol Biosci. 2020 Sep 30;7:588618. doi: 10.3389/fmolb.2020.588618.

50. Adedeji, A. O., and Sarafianos, S. G. (2014). Antiviral drugs specific for coronaviruses in preclinical development. Curr. Opin. Virol. 8, 45–53. doi: 10.1016/j.coivo.2014.06.002

51. Zhang Y, CaoW, JiangW, et al. Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020;50(3):580- 586. doi:10.1007/s11239-020-02182-9

52. Zaid Y, Puhm F, Allaey S, et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020. doi:10. 1161/CIRCRESAHA.120.317703

53. Nicolai L, Leunig A, Brambs S, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142(12):1176- 1189. doi:10.1161/CIRCULATIONAHA.120.048488

54. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383 (2):120-128. doi:10.1056/NEJMoa2015432

55. Lodigiani C, Iapichino G, Carenzo L, et al; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. doi:10.1016/j. thromres.2020.04.024

56. Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020; 136(11):1347-1350. doi:10.1182/blood.2020008086

57. Moores LK, Tritschler T, Brosnahan S, et al Prevention, diagnosis and treatment of venous
thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.

Chest. 2020;158:1143-1163. doi:10.1016/j.chest.2020.05.559

58. Spyropoulos AC, Levy JH, AgenoW, et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865. doi:10.1111/jth.14929

59. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 2020; 21 : 1336–45.

60. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; published online Sept 29.
   https://doi.org/10.1056/NEJMoa2028436.

61. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of are combinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 396 : 479–88.

62. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1/2 studies from Russia. Lancet 2020; 396 : 887–97.

63. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; published online Sept 2.
   https://doi.org/10.1056/NEJMoa2026920

64. Van Tendeloo, VF, Ponsaerts, P and Berneman. mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther. 2007 Oct ;9(5) :423-31.

65. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003 Oct 17 ;302(5644) :415-9.

66. Wolff, JA, Malone, RW, Williams, et al. (1990). Direct gene transfer into mouse muscle in vivo. Science 247 : 1465–1468.

67. Gilboa, E and Vieweg, J (2004). Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199 : 251–263.

68. Pascolo, S (2008). Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 183 : 221–235.

69. Alexopoulou, L, Holt, AC, Medzhitov, R, et al (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413 : 732–738.

70. Diebold, SS, Kaisho, T, Hemmi, H, et al (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 : 1529–1531.

71. Heil, F, Hemmi, H, Hochrein, H, et al. (2004). Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303 : 1526–1529.
72. Karikó, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165–175.

73. Karikó, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165–175.

74. Hornung, V, Ellegast, J, Kim, S, Brzozka, K, Jung, A, Kato, H et al. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science 314 : 994–997.

75. Karikó, K, Buckstein, M, Ni, H and Weissman, D (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23: 165–175.

76. Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008 ; 16 : 1833-40.

77. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med 2020 ; published online Oct 14. https://doi.org/ 10.1056/NEJMoa2027906.

78. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of are combinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020 ; 396 : 479–88.

79. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1/2 studies from Russia. Lancet 2020 ; 396 : 887–97.

80. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2020 ; published online Oct 15. https://doi.org/10.1016/

81. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020 ; 324 : 951–60.

82. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020 ; 367 : 1260-3.

83. Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2 neutralising antibodies and T cells in humans. December 11, 2020. (Https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1).preprint

84. Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015; 217: 345-51
85. Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615.

86. Baden LR, El Sahly HM, Essink B et al; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416.

87. Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 Jan 9;397(10269):99-111.

88. Ramasamy MN, Minassian AM, Ewer KJ, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 Dec 19;396(10267):1979-1993.

89. Abbink P, Lemckert AAC, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81: 4654-63.

90. Bos R, Rutten L, van der Lubbe JEM, et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines 2020; 5: 91.

91. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 10.1056/NEJMoa2034201.

92. Sadoff J, Gray G, Vandeboesch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.N Engl J Med. 2021 Apr 21. doi: 10.1056/NEJMoa2101544. Online ahead of print

93. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-1854.

94. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8. Epub 2021 Feb 2. Erratum in: Lancet. 2021 Feb 20;397(10275):670.

95. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis 2020; published online Oct 15. https://doi.org/10.1016/S1473-3099(20)30831-8.
96. Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 2020;
324: 951–60.

97. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; published online Sept 2. https://doi.org/10.1056/NEJMoa2026920.

98. ECDC-European Center for Disease Control. SARS-CoV-2 variants of concern as of 6 May 2021. available at "https://www.ecdc.europa.eu/en/covid-19/variants-concern"

99. A new coronavirus associated with human respiratory disease in China Nature volume 579, pages265–269(2020) https://doi.org/10.1038/s41586-020-2639-4

100. Edward E. Walsh Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates N Engl J Med 2020;383:2439-50. DOI: 10.1056/NEJMoa2027906

101. Fernando P. Polack, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine N Engl J Med 2020;383:2603-15. DOI: 10.1056/NEJMoa2034577

102. L.A. Jackson An mRNA Vaccine against SARS-CoV-2— Preliminary Report N Engl J Med 2020;383:1920-31. DOI: 10.1056/NEJMoa2022483

103. C. Keech, Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine N Engl J Med 2020;383:2320-32. DOI: 10.1056/NEJMoa2026920

104. L.R. Baden, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-16.DOI: 10.1056/NEJMoa2035389

105. Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant doi: https://doi.org/10.1101/2021.02.25.21252477

106. Neutralizing Activity of BNT162b2-Elicited Serum April 15, 2021 N Engl J Med 2021; 384:1466-1468 DOI: 10.1056/NEJMc2102017

107. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine April 15, 2021 N Engl J Med 2021; 384:1468-1470 DOI: 10.1056/NEJMc2102179

108. John P. Moore, PhD1; Paul A. Offit, MD2 SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

109. Nicole Lurie, MD, MSPH1; Joshua M. Sharfstein, MD2; Jesse L. Goodman, MD, MPH3. The Development of COVID-19 Vaccines Safeguards Needed. JAMA. 2020;324(5):439-440. doi:10.1001/jama.2020.12461

110. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1

111. https://www.sciencemag.org/news/2021/02/south-africa-suspends-use-astrazenecas-covid-19-vaccine-after-it-fails-clearly-stop

112. Nature ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques https://doi.org/10.1038/s41586-020-2608-y
113. Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 2020; published online Sept 2. https://doi.org/10.1056/NEJMoA2026920.

114. WHO World Health Organization. Buthan. The current Covid.19 situation. Available at https://www.who.int/countries/btn/. last update May 11, 2021.

115. Patterns of COVID-19 pandemic dynamics following deployment of a broad national immunization program. Nature Medicine doi: 10.1038/s41591-021-01337-2

116. Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland:

117. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers. May 6, 2021 N Engl J Med 2021; 384:1775-1777 DOI: 10.1056/NEJMc2101951

118. https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer

119. https://www.sciencemediacentre.org/expert-reaction-to-preprint-looking-at-the-pfizer-biontech-covid-19-vaccine-efficacy-in-israel/

120. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development

121. https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-it-has-shipped-variant-specific-vaccine

122. Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant doi: https://doi.org/10.1101/2021.02.25.21252477

123. IHME. COVID-19 vaccine efficacy summary, April 26, 2021 available at "http://www.healthdata.org/covid/covid-19-vaccine-efficacy-summary"

124. ECDC-European Center for Disease Control. SARS-CoV-2 variants of concern as of 6 May 2021. available at "https://www.ecdc.europa.eu/en/covid-19/variants-concern"

125. 23/04/2021 Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - EMEA/H/C/005675 - IB/0013 available at https://www.ema.europa.eu/documents/all-authorised-presentations/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-all-authorised-presentation_en.pdf

126. Greinacher A, Mayerle J, Aebischer A, et al. Anti-SARS-CoV-2 Spike Protein and Anti-Platelet Factor 4 Antibody Responses Induced by COVID-19 Disease and ChAdOx1 nCov-19 vaccination Research Gate 2021; 10.21203/rs.3.rs-404769/v1

127. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021 Apr 9. doi: 10.1056/NEJMoA2104882.

128. Goldman, M. Autoimmune Thrombotic Thrombocytopenia Associated with COVID-19 Infection or Vaccination: Learning from Heparin-induced Thrombocytopenia. Preprints 2021, 2021040255
129. Nguyen TH, Medvedev N, Delcea M, Greinacher A. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun. 2017 May 22;8:14945. doi: 10.1038/ncomms14945.

130. Wise J Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ2021;372:n699. doi:10.1136/bmj.n699 pmid:33707182

131. Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, Lidegaard Ø, Tapia G, Gulseth HL, Ruiz PL, Watle SV, Mikkelsen AP, Pedersen L, Sørensen HT, Thomsen RW, Hviid A. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021 May 5;373:n1114. doi: 10.1136/bmj.n1114.

132. European Medicines Agency (EMA). COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks - Update. https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-investigating-cases-thromboembolic-events-vaccines-benefits.

133. EMA. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021 available at https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021

134. Muir K-L, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. DOI: 10.1056/NEJMc2105869.

135. Sadoff J, Davis K, Douoguih M. Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer. N Engl J Med. 2021 Apr 16. doi: 10.1056/NEJMc2106075. Epub ahead of print. PMID: 33861522.